Search research articles
Contact Us
Filters
Showing results (11-20 of 14) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 14 results.
Journal of Pharmacological and Toxicological Methods
|
January 3, 2013
A simple whole blood bioassay detects cytokine responses to anti-CD28SA and anti-CD52 antibodies
Lucy Bailey, Laura Moreno, Tobias Manigold, et al.
The British Journal of Dermatology
|
November 15, 2025
Indeterminate Dendritic Cell Histiocytosis Harboring ETV3::NCOA2 Translocation with Complete Metabolic Response to MEK Inhibition
Vyshnavi Rallapalle, Jennifer Toral-Orduno, Brinda Shukla, et al.
Trials
|
October 3, 2020
The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor
Samantha Hinsley, Katrina Walker, Debbie Sherratt, et al.
British Journal of Haematology
|
February 18, 2026
Systemic Xanthogranuloma or Erdheim-Chester disease: A systematic review re-examining the classification challenge
Vyshnavi Rallapalle, Sailesh I S Kumar, Brinda Shukla, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 14) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 14 results.
Journal of Pharmacological and Toxicological Methods
|
January 3, 2013
A simple whole blood bioassay detects cytokine responses to anti-CD28SA and anti-CD52 antibodies
Lucy Bailey, Laura Moreno, Tobias Manigold, et al.
The British Journal of Dermatology
|
November 15, 2025
Indeterminate Dendritic Cell Histiocytosis Harboring ETV3::NCOA2 Translocation with Complete Metabolic Response to MEK Inhibition
Vyshnavi Rallapalle, Jennifer Toral-Orduno, Brinda Shukla, et al.
Trials
|
October 3, 2020
The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor
Samantha Hinsley, Katrina Walker, Debbie Sherratt, et al.
British Journal of Haematology
|
February 18, 2026
Systemic Xanthogranuloma or Erdheim-Chester disease: A systematic review re-examining the classification challenge
Vyshnavi Rallapalle, Sailesh I S Kumar, Brinda Shukla, et al.
Page
of 2